Cargando…
Relevance of a molecular tumour board (MTB) for patients’ enrolment in clinical trials: experience of the Institut Curie
BACKGROUND: High throughput molecular screening techniques allow the identification of multiple molecular alterations, some of which are actionable and can be targeted by molecularly targeted agents (MTA). We aimed at evaluating the relevance of using this approach in the frame of Institut Curie Mol...
Autores principales: | Basse, Clémence, Morel, Claire, Alt, Marie, Sablin, Marie Paule, Franck, Coralie, Pierron, Gaëlle, Callens, Céline, Melaabi, Samia, Masliah-Planchon, Julien, Bataillon, Guillaume, Gardrat, Sophie, Lavigne, Marion, Bonsang, Benjamin, Vaflard, Pauline, Pons Tostivint, Elvire, Dubot, Coraline, Loirat, Delphine, Marous, Miguelle, Geiss, Romain, Clément, Nathalie, Schleiermacher, Gudrun, Kamoun, Choumouss, Girard, Elodie, Ardin, Maude, Benoist, Camille, Bernard, Virginie, Mariani, Odette, Rouzier, Roman, Tresca, Patricia, Servois, Vincent, Vincent-Salomon, Anne, Bieche, Ivan, Le Tourneau, Christophe, Kamal, Maud |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890857/ https://www.ncbi.nlm.nih.gov/pubmed/29636991 http://dx.doi.org/10.1136/esmoopen-2018-000339 |
Ejemplares similares
-
Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy
por: Vaflard, Pauline, et al.
Publicado: (2021) -
Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial
por: Basse, Clémence, et al.
Publicado: (2018) -
Fine‐needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next‐generation sequencing in cancer patients included in the SHIVA02 trial
por: Dupain, Célia, et al.
Publicado: (2020) -
Acquired Exon 14 MET Mutation Associated With Resistance to Alectinib in a Patient With ALK–Rearranged NSCLC
por: Daniel, Catherine, et al.
Publicado: (2020) -
Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents
por: Le Tourneau, C, et al.
Publicado: (2012)